BO
BOLT.US Bolt Biotherapeutics
- Market cap
- USD 14.3M
- P/E
- -
- P/B
- 1.10x
- ROE
- -301.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BOLT.US undervalued?
Graham numberThe Graham number of Bolt Biotherapeutics cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bolt Biotherapeutics fundamental analysis
No fundamental analysis for Bolt Biotherapeutics yet.
Bolt Biotherapeutics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment o…
Full company profileBolt Biotherapeutics financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bolt Biotherapeutics annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 215K | 231K | 1.26M | 5.73M | 7.88M | 7.69M | 7.70M | - |
| Gross Profit | -302K | 215K | -40.1M | -74.4M | -67.4M | -53.7M | 7.69M | 6.20M | - |
| Operating Income | -11.6M | -31.0M | -49.2M | -92.8M | -90.3M | -76.2M | -73.0M | -34.6M | -27.6M |
| EBITDA | -11.3M | -30.6M | -48.6M | -97.4M | -86.4M | -67.3M | -66.5M | -32.1M | -25.3M |
| Net Income | -11.6M | -30.5M | -60.7M | -98.6M | -88.1M | -69.2M | -63.1M | -33.4M | -25.8M |
| EPS | -119 | -76 | -34 | -53 | -47 | -37 | -33 | -18 | -13 |
| Balance Sheet | |||||||||
| Total Assets | 16.0M | 48.4M | 46.5M | 308M | 228M | 160M | 99.6M | 56.7M | 35.6M |
| Total Liabilities | 31.9M | 94.3M | 151M | 57.6M | 56.3M | 47.0M | 42.4M | 30.2M | 27.0M |
| Shareholders' Equity | -15.9M | -45.8M | -105M | 250M | 172M | 113M | 57.2M | 26.5M | 8.56M |
| Cash & Short-term Investments | 13.6M | 34.8M | 22.8M | 186M | 169M | 102M | 47.3M | 27.5M | 14.8M |
| Total Debt | 40.0K | 10.2M | 10.9M | 24.4M | 22.6M | 20.2M | 25.2M | 23.0M | 20.9M |
| Cash Flow | |||||||||
| Operating Cash Flow | -9.87M | -26.3M | -47.3M | -57.1M | -76.5M | -69.5M | -61.3M | -39.9M | -23.5M |
| Capital Expenditure | 290K | 508K | 3.26M | 2.34M | 1.95M | 206K | 41.0K | 72.0K | 10.7M |
| Free Cash Flow | -10.2M | -26.9M | -50.6M | -59.4M | -78.5M | -69.7M | -61.3M | -39.9M | -23.5M |
| Ratios | |||||||||
| ROE | - | - | - | -39.4% | -51.4% | -61.4% | -110.4% | -125.9% | -301.9% |
| ROA | -72.5% | -62.9% | -130.5% | -32.0% | -38.7% | -43.3% | -63.4% | -58.8% | -72.6% |
| Net Profit Margin | - | -14,180.0% | -26,289.2% | -7,824.7% | -1,537.8% | -878.6% | -820.8% | -433.7% | - |
| Debt to Equity | - | - | - | 0.10x | 0.13x | 0.18x | 0.44x | 0.87x | 2.44x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bolt Biotherapeutics dividends
Bolt Biotherapeutics has not paid dividends in the last 8 fiscal years.
Last stock split: 1:20 on Jun 9, 2025.
Who owns Bolt Biotherapeutics
- Insiders 5.40%
- Institutions 36.40%
- Public & others 58.21%
- Shares outstanding 2.36M
- Free float 1.62M
Top funds holding BOLT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 7.47K | 0.32% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 5.35K | 0.23% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 1.70K | 0.07% | 0.00% | Sep 2026 |
| BlackRock Diversified Equity Alpha Inst | 89.00 | 0.00% | 0.00% | Jul 2026 |
| Guggenheim Active Allocation Fund | 12.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding BOLT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sofinnova Ventures | 138K | 7.15% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 98.6K | 5.12% | +27.71% | Jun 2026 |
| Vivo Capital, LLC | 72.4K | 3.76% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 56.9K | 2.95% | +462.89% | Jun 2026 |
| T3 Companies, LLC | 38.0K | 1.97% | 0.00% | Jun 2026 |
| Pfizer Inc | 31.3K | 1.63% | 0.00% | Jun 2026 |
| Lynx1 Capital Management, LP | 30.8K | 1.60% | 0.00% | Jun 2026 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 27.5K | 1.43% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 19.1K | 0.99% | -33.59% | Jun 2026 |
| Shay Capital LLC | 15.4K | 0.80% | +3.58% | Jun 2026 |
| BlackRock Inc | 9.71K | 0.50% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.06K | 0.37% | 0.00% | Jun 2026 |
| Nan Fung Group Holdings Ltd | 5.00K | 0.26% | -82.91% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.15K | 0.16% | -1.38% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 3.10K | 0.16% | 0.00% | Jun 2026 |
| Goss Wealth Management LLC | 2.53K | 0.13% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 1.71K | 0.09% | +56.45% | Jun 2026 |
| Mercer Global Advisors Inc. | 292.00 | 0.02% | 0.00% | Jun 2026 |
| UBS Group AG | 255.00 | 0.01% | -67.60% | Jun 2026 |
| SBI Securities Co Ltd | 130.00 | 0.01% | +1,200.00% | Jun 2026 |
Bolt Biotherapeutics company profile
- Company name
- Bolt Biotherapeutics
- Ticker
- BOLT.US
- Exchange
- USA Stocks
- Listed since
- Feb 5, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Fiscal year end
- December
- Address
- 900 Chesapeake Drive, Redwood City, CA, United States, 94063
- Phone
- 650 665 9295
- Website
- boltbio.com
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, and the INSPIRE platform. It serves patients, clinical investigators, and biopharmaceutical partners. The company is based in Redwood City, California.
Bolt Biotherapeutics management
5- Dr. Sheila K. Gujrathi M.D.Co-Founder & Director · born 1970
- Dr. Miguel Sanjuan Ph.D.Founder & Strategic Scientific Advisor
- Dr. Ryan Sullivan Ph.D.Chief Scientific Officer
- Christina TroutVice President of Corporate Development
- Mr. Hector Ortega M.D.Chief Medical Officer